CD44 and head and neck cancer: 26-27 Nonetheless, as articulated by Sadasivam, et al. 28 (2020), questions about the clinical relevance of CSC quantification still arise, especially when specialists attempt to predict risks of malignant transformation and of key clinical parameters such as tumor stage, invasiveness, and metastatic potential, highlighting a conspicuous correlation between the elevated expression of CSC biomarkers, including CD44, and the adverse prognostic outcomes in Head and Neck cancers and OSCC.